Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Emmanuelle Waubant, MD, PhD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentNeurology
    Address675 Nelson Rising Lane
    San Francisco CA 94158
    Phone415-514-8199

       Biography 
       Awards and Honors
      Best Doctors in America2010Selected one of the "Best Doctors in America"
      UCSF2010Nominated for the Chancellor's Award for the Advancement of Women
      American Academy of Neurology2010Fellow of the American Academy of Neurology
      UCSF2010Nominated for the Outstanding Faculty Mentorship Award
      UCSF2008Nominated for the Outstanding Faculty Mentorship Award
      UCSF2011 Nominated for the Outstanding Faculty Mentorship Award
      UCSF2012 Nominated for the Outstanding Faculty Mentorship Award
      UCSF2013 Nominated for the Outstanding Faculty Mentorship Award
      American Neurological Association2013Fellow of the American Neurological Association

       Overview 
       Overview
      Dr Waubant trained as a neurologist in Toulouse, France. She continued her training as a neuroimmunology fellow in Dr Stephen Hauser’s UCSF laboratory, focusing on matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP), and their role in migration of lymphocytes through equivalents of the blood-brain barrier. In 1994, Dr Waubant returned to Toulouse to complete her 2-year junior faculty/chief residency in neurology. Dr Waubant later returned as a clinical research fellow at the UCSF MS Center with Dr Donald Goodkin. During that 3-year period, she furthered her in vitro MMP work to the study in the human disease that helped to understand the role of MMP-9 and TIMP-1 in patients with MS and their relationship to disease activity. After completing her clinical research training at the UCSF MS center, Dr Waubant returned to France to lead a clinical research center at Salpetriere Hospital in Paris for 2 years. She returned to the UCSF MS center in September 2001 as a faculty. She is also the Race to Erase MS Medical Director and coordinates clinical research collaborations between 6 American MS Centers of Excellence. With the support of the National MS Society, she has started a regional pediatric MS clinic at UCSF in January 2006 that she directs and has since seen over 300 patients with pediatric MS or related disorders. She is the editor of the first text book on Pediatric MS and related disorders. Dr Waubant is the Chair of the American Committee on Treatment and Research in MS and the Chair of the Pediatric MS Steering Committee.
      Dr Waubant’s specific interests include the translation of promising agents from the bench to the bedside, understanding factors that predict the response to MS therapies, and risk factors for pediatric MS susceptibility and disease modification. Currently, she is the lead investigator for a neuroprotection phase 2 trial of riluzole in early relapsing remitting MS supported by the National MS Society (NMSS), the co-lead investigator for a trial of vitamin D in relapsing-remitting MS sponsored by the NMSS and is the recipient of a large NIH grant to study risk factors in pediatric MS and their interactions.

       Interests
      Clinical trials for patients with MS, risk factors for MS and NMO, response to treatments for MS

       ORNG Applications 
       Featured Publications
       Websites
       In The News
       Faculty Mentoring
       Awarded Grants
       Global Health

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Cantarel BL, Waubant E, Chehoud C, Kuczynski J, DeSantis TZ, Warrington J, Venkatesan A, Fraser CM, Mowry EM. Gut microbiota in multiple sclerosis: possible influence of immunomodulators. J Investig Med. 2015 Jun; 63(5):729-34.
        View in: PubMed
      2. Wilson LS, Loucks A, Gipson G, Zhong L, Bui C, Miller E, Owen M, Pelletier D, Goodin D, Waubant E, McCulloch CE. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis. Int J MS Care. 2015 Mar-Apr; 17(2):74-82.
        View in: PubMed
      3. Graves J, Grandhe S, Weinfurtner K, Krupp L, Belman A, Chitnis T, Ness J, Weinstock-Guttman B, Gorman M, Patterson M, Rodriguez M, Lotze T, Aaen G, Mowry EM, Rose JW, Simmons T, Casper TC, James J, Waubant E. Protective environmental factors for neuromyelitis optica. Neurology. 2014 Nov 18; 83(21):1923-9.
        View in: PubMed PMC4248458
      4. Gourraud PA, Henry RG, Cree BA, Crane JC, Lizee A, Olson MP, Santaniello AV, Datta E, Zhu AH, Bevan CJ, Gelfand JM, Graves JS, Goodin DS, Green AJ, von Büdingen HC, Waubant E, Zamvil SS, Crabtree-Hartman E, Nelson S, Baranzini SE, Hauser SL. Precision medicine in chronic disease management: The multiple sclerosis BioScreen. Ann Neurol. 2014 Nov; 76(5):633-42.
        View in: PubMed PMC4214886
      5. Bhargava P, Cassard S, Steele SU, Azevedo C, Pelletier D, Sugar EA, Waubant E, Mowry EM. The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp Clin Trials. 2014 Nov; 39(2):288-93.
        View in: PubMed
      6. Ayscue P, Van Haren K, Sheriff H, Waubant E, Waldron P, Yagi S, Yen C, Clayton A, Padilla T, Pan C, Reichel J, Harriman K, Watt J, Sejvar J, Nix WA, Feikin D, Glaser C. Acute flaccid paralysis with anterior myelitis - California, June 2012-June 2014. MMWR Morb Mortal Wkly Rep. 2014 Oct 10; 63(40):903-6.
        View in: PubMed
      7. Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach IV, Bucci M, Caverzasi E, Gelfand JM, Green AJ, Jordan KM, Stern WA, von Büdingen HC, Waubant E, Zhu AH, Goodin DS, Cree BA, Hauser SL, Henry RG. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol. 2014 Oct; 76(4):568-80.
        View in: PubMed
      8. Maghzi AH, Revirajan N, Julian LJ, Spain R, Mowry EM, Liu S, Jin C, Green AJ, McCulloch CE, Pelletier D, Waubant E. Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis. Mult Scler Relat Disord. 2014 Nov; 3(6):720-7.
        View in: PubMed
      9. Wilson L, Loucks A, Bui C, Gipson G, Zhong L, Schwartzburg A, Crabtree E, Goodin D, Waubant E, McCulloch C. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices. J Neurol Sci. 2014 Sep 15; 344(1-2):80-7.
        View in: PubMed
      10. Chitnis T, Waubant E. B-cell depletion in children with neuroimmunologic conditions: the learning curve. Neurology. 2014 Jul 8; 83(2):111-2.
        View in: PubMed
      11. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014 Jul 15; 83(3):278-86.
        View in: PubMed PMC4117366
      12. Waubant E, Maghzi AH, Revirajan N, Spain R, Julian L, Mowry EM, Marcus J, Liu S, Jin C, Green A, McCulloch CE, Pelletier D. A randomized controlled phase II trial of riluzole in early multiple sclerosis. Ann Clin Transl Neurol. 2014 May; 1(5):340-7.
        View in: PubMed PMC4184685
      13. Charvet LE, O'Donnell EH, Belman AL, Chitnis T, Ness JM, Parrish J, Patterson M, Rodriguez M, Waubant E, Weinstock-Guttman B, Krupp LB. Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network. Mult Scler. 2014 Oct; 20(11):1502-10.
        View in: PubMed
      14. Zhang J, Waubant E, Cutter G, Wolinsky J, Leppert D. Composite end points to assess delay of disability progression by MS treatments. Mult Scler. 2014 Oct; 20(11):1494-501.
        View in: PubMed
      15. Kraus V, Lawson EF, von Scheven E, Tihan T, Garza J, Nathan RG, Cordoro KM, Waubant E. Atypical cases of scleroderma en coup de sabre. J Child Neurol. 2014 May; 29(5):698-703.
        View in: PubMed
      16. Graves J, Kraus V, Soares BP, Hess CP, Waubant E. Longitudinally extensive optic neuritis in pediatric patients. J Child Neurol. 2015 Jan; 30(1):120-3.
        View in: PubMed
      17. Beres SJ, Graves J, Waubant E. Rituximab use in pediatric central demyelinating disease. Pediatr Neurol. 2014 Jul; 51(1):114-8.
        View in: PubMed
      18. Waubant E, Cross A. MS and related disorders: groundbreaking news. Lancet Neurol. 2014 Jan; 13(1):11-3.
        View in: PubMed
      19. Chitnis T, Guttmann CR, Zaitsev A, Musallam A, Weinstock-Guttman B, Yeh A, Rodriguez M, Ness J, Gorman MP, Healy BC, Kuntz N, Chabas D, Strober JB, Waubant E, Krupp L, Pelletier D, Erickson B, Bergsland N, Zivadinov R. Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. BMC Neurol. 2013; 13:173.
        View in: PubMed PMC3832402
      20. Graves J, Vinayagasundaram U, Mowry EM, Matthews IR, Marino JA, Cheng J, Waubant E. Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica. Mult Scler Relat Disord. 2014 Mar; 3(2):244-52.
        View in: PubMed
      21. Mowry EM, Carey RF, Blasco MR, Pelletier J, Duquette P, Villoslada P, Malikova I, Roger E, Kinkel RP, McDonald J, Bacchetti P, Waubant E. Association of multiple sclerosis susceptibility variants and early attack location in the CNS. PLoS One. 2013; 8(10):e75565.
        View in: PubMed PMC3794979
      22. Mowry EM, Carey RF, Blasco MR, Pelletier J, Duquette P, Villoslada P, Malikova I, Roger E, Kinkel RP, McDonald J, Bacchetti P, Waubant E. Multiple sclerosis susceptibility genes: associations with relapse severity and recovery. PLoS One. 2013; 8(10):e75416.
        View in: PubMed PMC3793991
      23. Maghzi AH, Minagar A, Waubant E. Neuroprotection in multiple sclerosis: a therapeutic approach. CNS Drugs. 2013 Oct; 27(10):799-815.
        View in: PubMed
      24. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One. 2013; 8(7):e66308.
        View in: PubMed PMC3699597
      25. Van Haren K, Waubant E. Therapeutic advances in pediatric multiple sclerosis. J Pediatr. 2013 Sep; 163(3):631-7.
        View in: PubMed
      26. Marcus JF, Waubant EL. Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis. Neurohospitalist. 2013 Apr; 3(2):65-80.
        View in: PubMed PMC3726117
      27. Chitnis T, Tardieu M, Amato MP, Banwell B, Bar-Or A, Ghezzi A, Kornberg A, Krupp LB, Pohl D, Rostasy K, Tenembaum S, Waubant E, Wassmer E. International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology. 2013 Mar 19; 80(12):1161-8.
        View in: PubMed PMC3662305
      28. Lulu S, Waubant E. Humoral-targeted immunotherapies in multiple sclerosis. Neurotherapeutics. 2013 Jan; 10(1):34-43.
        View in: PubMed PMC3557366
      29. McElroy JP, Krupp LB, Johnson BA, McCauley JL, Qi Z, Caillier SJ, Gourraud PA, Yu J, Nathanson L, Belman AL, Hauser SL, Waubant E, Hedges DJ, Oksenberg JR. Copy number variation in pediatric multiple sclerosis. Mult Scler. 2013 Jul; 19(8):1014-21.
        View in: PubMed
      30. Waubant E, Mowry EM, Krupp L, Chitnis T, Yeh EA, Kuntz N, Ness J, Belman A, Milazzo M, Gorman M, Weinstock-Guttman B, Rodriguez M, James JA. Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. Mult Scler. 2013 Jun; 19(7):891-5.
        View in: PubMed PMC3665694
      31. Julian L, Serafin D, Charvet L, Ackerson J, Benedict R, Braaten E, Brown T, O'Donnell E, Parrish J, Preston T, Zaccariello M, Belman A, Chitnis T, Gorman M, Ness J, Patterson M, Rodriguez M, Waubant E, Weinstock-Guttman B, Yeh A, Krupp LB. Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol. 2013 Jan; 28(1):102-7.
        View in: PubMed PMC3652651
      32. Waubant E. Improving outcomes in multiple sclerosis through early diagnosis and effective management. Prim Care Companion CNS Disord. 2012; 14(5).
        View in: PubMed
      33. Zhang J, Waubant E, Cutter G, Wolinsky JS, Glanzman R. EDSS variability before randomization may limit treatment discovery in primary progressive MS. Mult Scler. 2013 May; 19(6):775-81.
        View in: PubMed
      34. Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, Gourraud PA, Brenneman D, Owen MC, Qualley P, Bucci M, Hauser SL, Pelletier D. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012 Aug; 72(2):234-40.
        View in: PubMed PMC3430977
      35. Cross AH, Waubant E. Antibodies to potassium channels in multiple sclerosis. N Engl J Med. 2012 Jul 12; 367(2):172-4.
        View in: PubMed
      36. Waubant E. Overview of treatment options in multiple sclerosis. J Clin Psychiatry. 2012 Jun; 73(6):e22.
        View in: PubMed
      37. Waubant E. Early recognition and diagnosis of multiple sclerosis. J Clin Psychiatry. 2012 Apr; 73(4):e14.
        View in: PubMed
      38. Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology. 2012 Apr 10; 78(15):1171-8.
        View in: PubMed PMC3320055
      39. Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler. 2012 Jul; 18(7):932-46.
        View in: PubMed
      40. Hosseini H, Mandat T, Waubant E, Agid Y, Lubetzki C, Lyon-Caen O, Stankoff B, Jedynak P, Cesaro P, Palfi S, Nguyen JP. Unilateral thalamic deep brain stimulation for disabling kinetic tremor in multiple sclerosis. Neurosurgery. 2012 Jan; 70(1):66-9.
        View in: PubMed
      41. Fay AJ, Mowry EM, Strober J, Waubant E. Relapse severity and recovery in early pediatric multiple sclerosis. Mult Scler. 2012 Jul; 18(7):1008-12.
        View in: PubMed
      42. Langer-Gould A, Zhang JL, Chung J, Yeung Y, Waubant E, Yao J. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology. 2011 Sep 20; 77(12):1143-8.
        View in: PubMed PMC3265045
      43. Teunissen CE, Tumani H, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Federiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Jimenez CR, Johnson MH, Killestein J, Krasulova E, Kuhle J, Magnone MC, Petzold A, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Deisenhammer F, Giovannoni G, Hemmer B. Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Mult Scler Int. 2011; 2011:246412.
        View in: PubMed PMC3195993
      44. Waubant E, Mowry EM, Krupp L, Chitnis T, Yeh EA, Kuntz N, Ness J, Chabas D, Strober J, McDonald J, Belman A, Milazzo M, Gorman M, Weinstock-Guttman B, Rodriguez M, Oksenberg JR, James JA. Common viruses associated with lower pediatric multiple sclerosis risk. Neurology. 2011 Jun 7; 76(23):1989-95.
        View in: PubMed PMC3109881
      45. Waubant EL. Preface: multiple sclerosis in the 21st century. Neurol Clin. 2011 May; 29(2):xiii-xiv.
        View in: PubMed
      46. Chitnis T, Krupp L, Yeh A, Rubin J, Kuntz N, Strober JB, Chabas D, Weinstock-Guttmann B, Ness J, Rodriguez M, Waubant E. Pediatric multiple sclerosis. Neurol Clin. 2011 May; 29(2):481-505.
        View in: PubMed
      47. Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One. 2011; 6(2):e16664.
        View in: PubMed PMC3033401
      48. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb; 69(2):292-302.
        View in: PubMed PMC3084507
      49. Okuda DT, Mowry EM, Cree BA, Crabtree EC, Goodin DS, Waubant E, Pelletier D. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology. 2011 Feb 22; 76(8):686-92.
        View in: PubMed PMC3053327
      50. Mowry EM, James JA, Krupp LB, Waubant E. Vitamin D status and antibody levels to common viruses in pediatric-onset multiple sclerosis. Mult Scler. 2011 Jun; 17(6):666-71.
        View in: PubMed PMC3134182
      51. Yeh EA, Waubant E, Krupp LB, Ness J, Chitnis T, Kuntz N, Ramanathan M, Belman A, Chabas D, Gorman MP, Rodriguez M, Rinker JR, Weinstock-Guttman B. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol. 2011 Apr; 68(4):437-44.
        View in: PubMed
      52. Mowry EM, Waubant E. Pediatric multiple sclerosis. Continuum (Minneap Minn). 2010 Oct; 16(5 Multiple Sclerosis):181-92.
        View in: PubMed
      53. Mowry EM, Julian LJ, Im-Wang S, Chabas D, Galvin AJ, Strober JB, Waubant E. Health-related quality of life is reduced in pediatric multiple sclerosis. Pediatr Neurol. 2010 Aug; 43(2):97-102.
        View in: PubMed
      54. Cross AH, Waubant E. MS and the B cell controversy. Biochim Biophys Acta. 2011 Feb; 1812(2):231-8.
        View in: PubMed
      55. Kruer MC, Koch TK, Bourdette DN, Chabas D, Waubant E, Mueller S, Moscarello MA, Dalmau J, Woltjer RL, Adamus G. NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology. 2010 May 4; 74(18):1473-5.
        View in: PubMed PMC2872802
      56. Mowry EM, Krupp LB, Milazzo M, Chabas D, Strober JB, Belman AL, McDonald JC, Oksenberg JR, Bacchetti P, Waubant E. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol. 2010 May; 67(5):618-24.
        View in: PubMed
      57. O'Connor KC, Lopez-Amaya C, Gagne D, Lovato L, Moore-Odom NH, Kennedy J, Krupp L, Tenembaum S, Ness J, Belman A, Boyko A, Bykova O, Mah JK, Stoian CA, Waubant E, Kremenchutzky M, Ruggieri M, Bardini MR, Rensel M, Hahn J, Weinstock-Guttman B, Yeh EA, Farrell K, Freedman MS, Iivanainen M, Bhan V, Dilenge M, Hancock MA, Gano D, Fattahie R, Kopel L, Fournier AE, Moscarello M, Banwell B, Bar-Or A. Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. J Neuroimmunol. 2010 Jun; 223(1-2):92-9.
        View in: PubMed
      58. Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, Calabresi PA, Waubant E, Hauser SL, Zhang J, Smith CH. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010 Apr; 67(4):452-61.
        View in: PubMed
      59. Kuntz NL, Chabas D, Weinstock-Guttman B, Chitnis T, Yeh EA, Krupp L, Ness J, Rodriguez M, Waubant E. Treatment of multiple sclerosis in children and adolescents. Expert Opin Pharmacother. 2010 Mar; 11(4):505-20.
        View in: PubMed
      60. Chabas D, Ness J, Belman A, Yeh EA, Kuntz N, Gorman MP, Strober JB, De Kouchkovsky I, McCulloch C, Chitnis T, Rodriguez M, Weinstock-Guttman B, Krupp LB, Waubant E. Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology. 2010 Feb 2; 74(5):399-405.
        View in: PubMed PMC2816008
      61. Cree B, Waubant E. Does race matter for multiple sclerosis? Neurology. 2010 Feb 16; 74(7):532-3.
        View in: PubMed
      62. Teunissen CE, Tumani HT, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Federiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Petzold A, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Hemmer B, Deisenhammer F, Giovannoni G. Short commentary on 'a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking'. Mult Scler. 2010 Feb; 16(2):129-32.
        View in: PubMed
      63. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Giovannoni G, Hemmer B, Tumani H, Deisenhammer F. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009 Dec 1; 73(22):1914-22.
        View in: PubMed PMC2839806
      64. Yeh EA, Chitnis T, Krupp L, Ness J, Chabas D, Kuntz N, Waubant E. Pediatric multiple sclerosis. Nat Rev Neurol. 2009 Nov; 5(11):621-31.
        View in: PubMed
      65. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009 Oct; 66(4):460-71.
        View in: PubMed
      66. Waubant E, Chabas D, Okuda DT, Glenn O, Mowry E, Henry RG, Strober JB, Soares B, Wintermark M, Pelletier D. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol. 2009 Aug; 66(8):967-71.
        View in: PubMed
      67. Smith CH, Waubant E, Langer-Gould A. Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population. J Neuroophthalmol. 2009 Jun; 29(2):104-6.
        View in: PubMed
      68. Mowry EM, Beheshtian A, Waubant E, Goodin DS, Cree BA, Qualley P, Lincoln R, George MF, Gomez R, Hauser SL, Okuda DT, Pelletier D. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology. 2009 May 19; 72(20):1760-5.
        View in: PubMed PMC2683738
      69. Waubant E, Chabas D. Pediatric multiple sclerosis. Curr Treat Options Neurol. 2009 May; 11(3):203-10.
        View in: PubMed
      70. Mehta LR, Schwid SR, Arnold DL, Cutter GR, Aradhye S, Balcer LJ, Calabresi PA, Cohen JA, Cole PE, Glanzman R, Goelz S, Inglese M, Kapoor R, Kappos L, Kreitman R, Lublin FD, Mann A, Marrie RA, O'Looney P, Polman CH, Ravina BM, Reingold SC, Richert JR, Sandrock AW, Waubant E. Proof of concept studies for tissue-protective agents in multiple sclerosis. Mult Scler. 2009 May; 15(5):542-6.
        View in: PubMed
      71. Mowry EM, Pesic M, Grimes B, Deen SR, Bacchetti P, Waubant E. Clinical predictors of early second event in patients with clinically isolated syndrome. J Neurol. 2009 Jul; 256(7):1061-6.
        View in: PubMed PMC2708331
      72. Mowry EM, Pesic M, Grimes B, Deen S, Bacchetti P, Waubant E. Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology. 2009 Feb 17; 72(7):602-8.
        View in: PubMed PMC2677540
      73. Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, Hauser SL, Pelletier D. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009 Mar 3; 72(9):800-5.
        View in: PubMed
      74. Mowry EM, Deen S, Malikova I, Pelletier J, Bacchetti P, Waubant E. The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry. 2009 Apr; 80(4):400-3.
        View in: PubMed
      75. Okuda DT, Srinivasan R, Oksenberg JR, Goodin DS, Baranzini SE, Beheshtian A, Waubant E, Zamvil SS, Leppert D, Qualley P, Lincoln R, Gomez R, Caillier S, George M, Wang J, Nelson SJ, Cree BA, Hauser SL, Pelletier D. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain. 2009 Jan; 132(Pt 1):250-9.
        View in: PubMed PMC2638695
      76. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, Geurts JJ, Kragt J, Sombekke M, Vrenken H, Qualley P, Lincoln RR, Gomez R, Caillier SJ, George MF, Mousavi H, Guerrero R, Okuda DT, Cree BA, Green AJ, Waubant E, Goodin DS, Pelletier D, Matthews PM, Hauser SL, Kappos L, Polman CH, Oksenberg JR. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet. 2009 Feb 15; 18(4):767-78.
        View in: PubMed
      77. Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler. 2009 Jan; 15(1):50-8.
        View in: PubMed
      78. Chabas D, Castillo-Trivino T, Mowry EM, Strober JB, Glenn OA, Waubant E. Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype? Neurology. 2008 Sep 30; 71(14):1090-3.
        View in: PubMed
      79. Chabas D, Strober J, Waubant E. Pediatric multiple sclerosis. Curr Neurol Neurosci Rep. 2008 Sep; 8(5):434-41.
        View in: PubMed
      80. Waubant E. Spotlight on anti-CD20. Int MS J. 2008 Mar; 15(1):19-25.
        View in: PubMed
      81. Bar-Or A, Calabresi PA, Arnold D, Arnlod D, Markowitz C, Shafer S, Kasper LH, Waubant E, Gazda S, Fox RJ, Panzara M, Sarkar N, Agarwal S, Smith CH. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008 Mar; 63(3):395-400.
        View in: PubMed
      82. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14; 358(7):676-88.
        View in: PubMed
      83. Deen S, Bacchetti P, High A, Waubant E. Predictors of the location of multiple sclerosis relapse. J Neurol Neurosurg Psychiatry. 2008 Oct; 79(10):1190-3.
        View in: PubMed
      84. Banwell B, Krupp L, Kennedy J, Tellier R, Tenembaum S, Ness J, Belman A, Boiko A, Bykova O, Waubant E, Mah JK, Stoian C, Kremenchutzky M, Bardini MR, Ruggieri M, Rensel M, Hahn J, Weinstock-Guttman B, Yeh EA, Farrell K, Freedman M, Iivanainen M, Sevon M, Bhan V, Dilenge ME, Stephens D, Bar-Or A. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol. 2007 Sep; 6(9):773-81.
        View in: PubMed
      85. Kantor AB, Deng J, Waubant E, Lin H, Becker CH, Lacy JR, Perrone AM, Bennett D, Goelz SE. Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling. J Neuroimmunol. 2007 Aug; 188(1-2):103-16.
        View in: PubMed
      86. Waubant E. Emerging therapies for MS. Rev Neurol (Paris). 2007 Jun; 163(6-7):688-96.
        View in: PubMed
      87. Belman AL, Chitnis T, Renoux C, Waubant E. Challenges in the classification of pediatric multiple sclerosis and future directions. Neurology. 2007 Apr 17; 68(16 Suppl 2):S70-4.
        View in: PubMed
      88. Pohl D, Waubant E, Banwell B, Chabas D, Chitnis T, Weinstock-Guttman B, Tenembaum S. Treatment of pediatric multiple sclerosis and variants. Neurology. 2007 Apr 17; 68(16 Suppl 2):S54-65.
        View in: PubMed
      89. West T, Wyatt M, High A, Bostrom A, Waubant E. Are initial demyelinating event recovery and time to second event under differential control? Neurology. 2006 Sep 12; 67(5):809-13.
        View in: PubMed
      90. Chabas D, Green AJ, Waubant E. Pediatric multiple sclerosis. NeuroRx. 2006 Apr; 3(2):264-75.
        View in: PubMed PMC3593440
      91. Waubant E. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis Markers. 2006; 22(4):235-44.
        View in: PubMed PMC3850823
      92. Okuda DT, Chyung AS, Chin CT, Waubant E. Acute pathological laughter. Mov Disord. 2005 Oct; 20(10):1389-90.
        View in: PubMed
      93. Waubant E, Sadovnick AD. Interferon beta babies. Neurology. 2005 Sep 27; 65(6):788-9.
        View in: PubMed
      94. Stankoff B, Waubant E, Confavreux C, Edan G, Debouverie M, Rumbach L, Moreau T, Pelletier J, Lubetzki C, Clanet M. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology. 2005 Apr 12; 64(7):1139-43.
        View in: PubMed
      95. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005 Apr 12; 64(7):1270-2.
        View in: PubMed
      96. Waubant E, Tezenas du Montcel S, Jedynak C, Obadia M, Hosseini H, Damier P, Lubetzki C, Agid Y, Degos JD. Multiple sclerosis tremor and the Stewart-Holmes manoeuvre. Mov Disord. 2003 Aug; 18(8):948-52.
        View in: PubMed
      97. Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S, Renoux C, Confavreux C. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology. 2003 Jul 22; 61(2):184-9.
        View in: PubMed
      98. Waubant E. Emerging disease modifying therapies for multiple sclerosis. Expert Opin Emerg Drugs. 2003 May; 8(1):145-61.
        View in: PubMed
      99. Waubant E, Goodkin D, Bostrom A, Bacchetti P, Hietpas J, Lindberg R, Leppert D. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology. 2003 Jan 14; 60(1):52-7.
        View in: PubMed
      100. Brassat D, Recher C, Waubant E, Le Page E, Rigal-Huguet F, Laurent G, Edan G, Clanet M. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology. 2002 Sep 24; 59(6):954-5.
        View in: PubMed
      101. Waubant E, Alizé P, Tourbah A, Agid Y. Paroxysmal dystonia (tonic spasm) in multiple sclerosis. Neurology. 2001 Dec 26; 57(12):2320-1.
        View in: PubMed
      102. Waubant E. [Therapeutic indications for managing symptoms: fatigue]. Rev Neurol (Paris). 2001 Sep; 157(8-9 Pt 2):1066-71.
        View in: PubMed
      103. Waubant E, Hietpas J, Stewart T, Dyme Z, Herbert J, Lacy J, Miller C, Rensel M, Schwid S, Goodkin D. Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics. 2001 Aug; 32(4):211-3.
        View in: PubMed
      104. Waubant E, Gee L, Miller K, Stabler G, Goodkin D. IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis. J Interferon Cytokine Res. 2001 Mar; 21(3):181-5.
        View in: PubMed
      105. Waubant E, Gee L, Bacchetti P, Sloan R, Cotleur A, Rudick R, Goodkin D. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS. J Neuroimmunol. 2001 Jan 1; 112(1-2):139-45.
        View in: PubMed
      106. Suhy J, Rooney WD, Goodkin DE, Capizzano AA, Soher BJ, Maudsley AA, Waubant E, Andersson PB, Weiner MW. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler. 2000 Jun; 6(3):148-55.
        View in: PubMed PMC2733351
      107. Kita M, Goodkin DE, Bacchetti P, Waubant E, Nelson SJ, Majumdar S. Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a. Neurology. 2000 May 9; 54(9):1741-5.
        View in: PubMed
      108. Goodkin DE, Shulman M, Winkelhake J, Waubant E, Andersson P, Stewart T, Nelson S, Fischbein N, Coyle PK, Frohman E, Jacobs L, Holcenberg J, Lee M, Mocci S. A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis. Neurology. 2000 Apr 11; 54(7):1414-20.
        View in: PubMed
      109. Waubant E, Goodkin D. Methodological problems in evaluating efficacy of a treatment in multiple sclerosis. Pathol Biol (Paris). 2000 Mar; 48(2):104-13.
        View in: PubMed
      110. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson PB, Stabler G, Miller K. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology. 1999 Oct 22; 53(7):1397-401.
        View in: PubMed
      111. Waubant E, Goodkin DE, Sloan R, Andersson PB. A pilot study of MRI activity before and during interferon beta-1a therapy. Neurology. 1999 Sep 11; 53(4):874-6.
        View in: PubMed
      112. Andersson PB, Waubant E, Gee L, Goodkin DE. Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. Arch Neurol. 1999 Sep; 56(9):1138-42.
        View in: PubMed
      113. Waubant E, Goodkin D. [How phase III therapeutic trials in multiple sclerosis should be evaluated: advances and challenges]. Rev Neurol (Paris). 1999; 155 Suppl 2:S7-12.
        View in: PubMed
      114. Waubant E, Sloan R, Andersson PB, Goodkin D. [Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis]. Rev Neurol (Paris). 1999; 155 Suppl 2:S20-3.
        View in: PubMed
      115. Goodkin DE, Rooney WD, Sloan R, Bacchetti P, Gee L, Vermathen M, Waubant E, Abundo M, Majumdar S, Nelson S, Weiner MW. A serial study of new MS lesions and the white matter from which they arise. Neurology. 1998 Dec; 51(6):1689-97.
        View in: PubMed
      116. Waubant E, Delisle MB, Bonafé A, Gray F, Clanet M. Cervical cord glioma in an HIV-positive patient. Eur Neurol. 1998; 39(1):58-60.
        View in: PubMed
      117. Waubant E, Simonetta-Moreau M, Clanet M, Berry I, Bonafé A. Left arm monoballism as a relapse in multiple sclerosis. Mov Disord. 1997 Nov; 12(6):1091-2.
        View in: PubMed
      118. Waubant E, Manelfe C, Bonafé A, Berry I, Clanet M. MRI of intramedullary sarcoidosis: follow-up of a case. Neuroradiology. 1997 May; 39(5):357-60.
        View in: PubMed
      119. Andersson PB, Waubant E, Goodkin DE. How should we proceed with disease-modifying treatments for multiple sclerosis? Lancet. 1997 Mar 1; 349(9052):586-7.
        View in: PubMed
      120. Leppert D, Waubant E, Bürk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol. 1996 Dec; 40(6):846-52.
        View in: PubMed
      121. Albucher JF, Carles P, Giron J, Waubant E, Guiraud-Chaumeil B, Chollet F, Clanet M. [Ischemic cerebrovascular complications in Rendu-Osler disease: a case]. Rev Neurol (Paris). 1996 Apr; 152(4):283-7.
        View in: PubMed
      122. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol. 1995 May 1; 154(9):4379-89.
        View in: PubMed
      Emmanuelle's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP